The pathophysiology and management of thrombotic thrombocytopenic purpura

European Journal of Haematology

Volumn 56, Issue 4, 1996, Pages 191-207

  Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Microangiopathy; Plasma manipulation; Thrombotic thrombocytopenic purpura; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXTRAN 70; DIPYRIDAMOLE; IMMUNOGLOBULIN; PREDNISOLONE; PREDNISONE; PROSTACYCLIN; SULFINPYRAZONE; TICLOPIDINE; VINCRISTINE;

BLOOD TRANSFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; THROMBOCYTOPENIC PURPURA; THROMBOSIS;

EID: 0030000015     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01930.x     Document Type: Review

References (144)

1. RUGGENENTI P, REMUZZI G. Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin North Am 1990: 4: 219.
2. MOSCHCOWITZ E. Acute febrile pleiochromic anemia with hyaline thrombosis of terminal arterioles and capillaries: an undescribed disease. Arch Intern Med 1925: 36: 89-93.
3. BAEHR G, KLEMPERER P, SCHIFRIN A. An acute febrile anemia and thrombocytopenic purpura with diffuse platelet thromboses of capillaries and arterioles. Tran Assoc Am Physicians 1936: 51: 43-58.
4. SINGER K, BORNSTEIN FP, WILE SA. Thrombotic thrombocytopenic purpura. Hemorrhagic diathesis with generalized platelet thromboses. Blood 1947: 2: 542-554.
5. GASSER C, GAUTIER E, STECK A, SIEBENMANN RE, DECHSLIN R. Hamolytisch-uramische syndromes bilaterale Nierenrindennekrosen bei akuten erworbenchen hamolytischen Anamien. Schweiz Med Wschr 1955: 85: 905-909.
6. ROSSI EC, GREEN D, DEL GRECO F. The use of inhibitors of platelet function in thrombotic microangiopathy. In: REMUZZI G, MECCA G, DE GAETANO G, eds. Hemostasis, Prostaglandins, and Renal Disease. New York: Raven Press: 1980: 413.
7. BUKOWSKI RM. Thrombotic thrombocytopenic purpura: A Review. In: SPAET TH, ed. Progress in Hemostasis and Thrombosis. New York: Grune & Stratton: 1982: 287-337.
8. MORRISON DM, TYRREL DL, JEWELL LD. Colonic biopsy in verotoxin-induced hemorrhagic colitis. Am J Clin Pathol 1986: 86: 108-112.
9. WINDLER F, WEH HJ, HOSSFELD DK, et al. Verotoxin in thrombotic thrombocytopenic purpura (letter). Eur J Haematol 1989: 42: 103.
10. AMOROSI EL, ULTMANN JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966: 45: 139-159.
11. KENNEDY SS, ZACHARSKI LR, BECK JR. Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases. Semin Thromb Hemost 1980: 6: 341-349.
12. O'BRIEN JL, SIBLEY WA. Neurologic manifestations of thrombotic thrombocytopenic purpura. Neurology 1958: 8: 55-63.
13. EKNOYAN G, RIGGS SA. Renal involvement in patients with thrombotic thrombocytopenic purpura. Am J Nephrol 1986: 6: 117-131.
14. BYRNES JJ, MOAKE JL, KLUG P, PERIMAN P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990: 34: 169-174.
15. TAFT EG, CARVER BB. Subacute (acute, persistent) thrombotic microangiopathy. J Clin Apheresis 1992: 7: 180-182.
16. ROSE M, ROWE JM, ELDOR A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood 1993: 7: 94-103.
17. SHUMWAY CN JR, MILLER G. An unusual syndrome of hemolytic anemia, thrombocytopenic purpura and renal disease. Blood 1957: 12: 1045-1060.
18. MACWHINNEY JB, PACKER JT, MILLER G. Thrombotic thrombocytopenic purpura in childhood. Blood 1962: 19: 181.
19. METTLER NE. Isolation of a microtatobioti from patients with hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura and from mites in the United States. N Engl J Med 1969: 281: 1023-1027.
20. ROSSI EC. Thrombotic thrombocytopenic purpura: a disseminate form of thrombotic microangiopathy. In: REMUZZI G, ROSSI EC, eds. Haemostasis and the kidney, 237th edn. London: Butterworths: 1989: 237.
21. WYATT RJ, JONES D, STAPLETON FB, ROY SIII, ODOM TW, MCLEAN RH. Recurrent hemolytic uremic syndrome with the hypomorphic fast allele of the third component of complement. J Pediatr 1985: 107: 564-566.
22. RUGGENENTI P, REMUZZI G, ROSSI EC. Epidemiology of the hemolytic uremic syndrome. N Engl J Med 1991: 324: 1065-1066.
23. MOAKE JL, RUDY CK, TROLL IH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982: 307: 1432-1435.
24. POWELL HR, DAVIDSON PM, MCCREDIE DA, PHAIR P, WALKER RG. Haemolytic uraemic syndrome after treatment with metronidazole. Med J Aust 1988: 149: 222-223.
25. TAYLOR CM, POWELL HR. Oxygen-derived free radicals in the pathogenesis of the hemolytic urecmic syndrome. In: KAPLAN BS, TROMPETER RS, MOAKE JL, eds. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker, Inc: 1992: 355-372.
26. REMUZZI G, MISIANI R, MARCUESI D, et al. Haemolytic uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet 1978: 2: 871-872.
27. REMUZZI G. Thrombotic thrombocytopenic purpura and allied disorders. In: VERSTRAETE M, VERMYLEN J, LIJNEN HR, ARNOUT J, eds. Thrombosis and Haemostasis. Leuven: Leuven University Press: 1987: 673-708.
28. REMUZZI G, ZOJA C, ROSSI EC, et al. Prostacyclin in thrombotic microangiopathy. Semin Thromb Hemost 1987: 6: 391-394.
29. CHEN YC, MCLEOD B, HALL ER, WU KK. Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura. Lancet 1981: 2: 267-269.
30. WU KK, HALL ER, ROSSI EC, PAPP AC. Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura. J Clin Invest 1985: 75: 168-174.
31. CASIRAGHI F, BENIGNI A, NORIS M, SIEGLER R, GASPARI F, REMUZZI G. Renal prostacyclin biosynthesis is selectively reduced in children with hemolytic uremic syndrome. JASN 1991: 2: 264 (abstract).
32. KWAAN HC. Role of fibrinolysis in thrombotic thrombocytopenic purpura. Semin Thromb Hemost 1979: 6: 395-400.
33. BERGSTEIN JM, BANG NU. Plasminogen activator inhibitor-1 (PAI-1) is the circulating ihibitor of fibrinolysis (PAI-HUS) in the hemolytic syndrome (HUS). Kidney Int 1989: 37: 254 (abstract).
34. BERGSTEIN GM, KUEDERLI Y, BANG NU. Plasma inhibitor of glomerular fibrinolysis in the hemolylic-uremic syndrome. Am J Med 1982: 73: 322-327.
35. PROESMANS W, VAN GEET C, ARNOUT J, DECLERCK P. Prospective study on coagulation and fibrinolysis in childhood hemolytic uremic syndrome (HUS). The Tenth Congress of the International Pediatric Nephrology Association 27 August/1 September, Santiago, Chile 1995: C44 (abstract).
36. MOAKE JL, BYRNES JJ, TROLL JH, et al. Abnormal VIII: von Willebrand factor patterns in the plasma of patients with the hemolytic uremic syndrome. Blood 1984: 64: 592-598.
37. KELTON JG, MOORE J, SANTOS A, SHERIDAN D. Detection of a platelet agglutinating factor in thrombotic thrombocytopenic purpura. Ann Intern Med 1984: 101: 589-592.
38. ROSE PE, ENAYAT SM, SUNDERLAND R, SHORT PE, WILLIAMS CE, HILL FGH. Abnormalities of factor VIII related protein multimers in the haemolytic uraemic syndrome. Arch Dis Child 1984: 59: 1135-1140.
39. MOAKE JL, MCPHERON PD. von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Trans Med Rev 1990: 4: 163-166.
40. FEDERICI AB, ELDER JH, DE MARCO L, RUGGERI ZM, ZIMMERMAN TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984: 74: 2049-2055.
41. HAMILTON KK, FRETTO LS, GRIERSON DS, MCKEE PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest 1985: 76: 261-270.
42. KUNICKI TJ, MONTGOMERY RR, SCHULLEK J. Cleavage of human von Willebrand factor by platelet calcium-activated protease. Blood 1985: 65: 352-356.
43. THOMPSON EA, HOWARD MA. Proteolytic cleavage of human von Willebrand factor induced by enzyme(s) released from polymorphonuclear cells. Blood 1986: 67: 1281-1285.
44. TSAI H-M, SUSSMAN H, NAGEL RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994: 83: 2171-2179.
45. MANNUCCI PM, LOMBARDI R, LATTUADA A, et al. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 1989: 74: 978-983.
46. MONCADA S, HIGGS A. The L arginine-nitric oxide pathway. N Engl J Med 1993: 329: 2002-2011.
47. MULLIGAN MS, HEVEL JM, MARLETTA MA, WARD PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991: 88: 6338-6342.
48. RUBANYI GM, ROMERO JC, VANHOUTTE PM. Flow-induced release of endothelium relaxing factor. Am J Physiol 1986: 250: H1145-H1149.
49. NORIS M, MORIGI M, ZOJA C, et al. Modulation of nitric oxide (NO) synthesis by endothelial cells in vitro is a function of flow conditions. JASN 1993: 4: 562 (abstract).
50. ESTRADA C, GOMEZ C, MARTIN C, MONCADA S, GONZALES C. Nitric oxide mediates tumor necrosis factor-α cytotoxicity in endothelial cells. Biochem Biophys Res Commun 1992: 186: 475-482.
51. LANDER HM, SEHAJPAL P, LEVINE DM, NOVOGRODSKY A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 1993: 150: 1509-1516.
52. BECKMAN JS, BECKMAN TW, CHEN J, MARSHALL PA, FREEMAN BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990: 87: 1620-1624.
53. NORIS M, ZOJA C, TODESCHINI M, et al. Serum from patients with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) induces nitric oxide (NO) synthesis in cultured endothelial cells. JASN 1994: 5: 402 (abstract).
54. VISCHER UM, JORNOT L, WOLLHEIM CB, THELER J-M. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood 1995: 85: 3164-3172.
55. LARSEN E, CELI A, GILBERT GE, et al. PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989: 59: 305.
56. MAYADAS TN, JOHNSON RC, RAYBURN H, HYNES RO, WAGNER DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993: 74: 541.
57. EDEFONTI A, TENTORI F, BETTINELLI A, et al. Pattern of platelet serotonin (5TH), plasma beta-thromboglobulin (betaTG) and platelet factor (PG4) in hemolytic-uremic syndrome (HUS) in children. Int J Pediatr Nephrol 1981: 2: 149.
58. FONG JSC, KAPLAN BS. Impairment of platelet aggregation in hemolytic uremic syndrome. Evidence for platelet "exhaustion". Blood 1982: 60: 564-570.
59. KAPLAN BS, FONG JSC. Reduced platelet aggregation in hemolytic uremic syndrome. Thromb Haemost 1980: 43: 154-157.
60. LIAN ECY, HARKNESS DR, BYRNES JJ, WALLACH H, NUNEZ R. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood 1979: 53: 333-338.
61. SIDDIQUI FA, LIAN ECY. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. J Clin Invest 1985: 76: 1330-1337.
62. LIAN ECY, SIDDIQUI FA, CHEN SH, FENG LM. Platelet-agglutinating/aggregating proteins from the plasma of patients with thrombotic thrombocytopenic purpura. In: KAPLAN BS, TROMPETER RS, MOAKE JL, eds. HUS and TTP. New York: Marcel Dekker, Inc: 1992: 473-481.
63. HIRAFUJI M, SHINODA H. Platelet-leukocyte interaction in adhesion to endothelial cells induced by platelet-activating factor in vitro. Br J Pharmacol 1991: 103: 1333-1338.
64. BENIGNI A, BOCCARDO P, NORIS M, REMUZZI G, SIEGLER RL. Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. Lancet 1992: 339: 835-836.
65. RIDOLFI RL, BELL WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine 1981: 60: 413-428.
66. BELL WR, BRAINE HG, NESS PM, KICKLER TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991: 325: 398-403.
67. ROCK GA, SHUMAK KH, BUSKARD NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991: 325: 393-397.
68. REMUZZI G, RUGGENENTI P, BERTANI T. Thrombotic microangiopathies. In: TISHER CC, BRENNER BM, eds. Renal Pathology, 2nd edn. Philadelphia: J. B. Lippincott: 1994: 1154-1184.
69. WILE SA, STURGEON P. Thrombotic thrombocytopenic purpura: Review of the subject with a report of three cases in children. Pediatrics 1956: 17: 882-896.
70. BUKOWSKI RM, HEWLETT JS, HARRIS JW. Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol 1976: 13: 219-232.
71. RUBINSTEIN MA, et al. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med 1959: 51: 1409.
72. MYERS TJ. Treatment of thrombocytopenic purpura with combined exchange plasmapheresis and anti-platelet agents. Semin Thromb Haemost 1981: 7: 37-42.
73. RUGGENENTI P, GALBUSERA M, PLATA CORNEJO R, BELLAVITA P, REMUZZI G. Thrombotic thrombocytopenic purpura: Evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993: 21: 314-318.
74. NOVITZKY N, JACOBS P, ROSENSTRAUCH W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? Br J Haematol 1994: 87: 317-320.
75. HAYWARD CP, SUTTON DM, CARTER WH JR, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994: 154: 982-987.
76. ELDOR A, MOSER AM, ROSE M, BEN-YEHUDA D, RACHMILEWITZ EA. Thrombotic thrombocytopenic purpura: the Israeli experience. Transfusion Sci 1992: 13: 53-57.
77. UPSHAW JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978: 298: 1350-1352.
78. REMUZZI G, MISIANI R, MECCA G, et al. Thrombotic thrombocytopenic purpura. A deficiency of plasma factors regulating platelet-vessel-wall interaction? N Engl J Med 1978: 299: 311.
79. ROSSI EC, REDONDO D, BORGES WH. Thrombotic thrombocytopenic purpura. Survival following treatment with aspirin, dipyridamole and prednisone. JAMA 1974: 228: 1141-1143.
80. CUTTNER J. Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura. JAMA 1974: 227: 397-402.
81. BIRGENS H, ERNST P, HANSEN MS. Thrombotic thrombocytopenic purpura: treatment with a combination of anti-platelet drugs. Acta Med Scand 1979: 205: 437-439.
82. FAGUET GB, KING MD. Thrombotic thrombocytopenic purpura: treatment with antiplatelet agents. Am J Med Sci 1974: 268: 113-116.
83. GUNDLACH WJ, TARNASKY R. Thrombotic thrombocytopenic purpura-remission following treatment with aspirin and dipyridamole. Minn Med 1977: 60: 20-21.
84. MARMONT AM, DAMASIO E, ROSS E, et al. Thrombotic thrombocytopenic purpura successfully treated with a combination of dipyridamole and aspirin. Haematologica 1980: 65: 222.
85. PHILLIPS MD. Antiplatelet agents in thrombotic thrombocytopenic purpura. In: KAPLAN BS, TROMPETER RS, MOAKE JL, eds. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, Inc: 1992: 531-540.
86. ROSOVE MH, HO WG, GOLDFINGER F. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982: 96: 27-33.
87. PAGE Y, TARDY B, ZENI F, COMTET C, TERRANA R, BERTRAND JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991: 337: 774-776.
88. GUTTERMAN LA, STEVENSON TD. Treatment of thrombotic thrombocytopenic purpura with vincristine. JAMA 1982: 247: 1433-1436.
89. O'CONNOR NT, BRUCE-JONES P, HILL LF. Vincristine therapy for thrombotic thrombocytopenic purpura. Am J Hematol 1992: 39 (3): 234-236.
90. LEVIN M, GRUNWALD HW. Use of vincristine in refractory thrombotic thrombocytopenic purpura. Acta Haematol 1991: 85: 37-40.
91. VIERO P, CORTELAZZO S, BUELLI M, COMOTTI B, MINETTI B. BARBUI T. Thrombotic thrombocytopenic purpura and high-dose immunoglobulin therapy. Ann Intern Med 1986: 104: 282.
92. KELTON JG, MOORE JC, MURPHY WG. Studies investigating platelet aggregation and release initiated by sera from patients with thrombotic thrombocytopenic purpura. Blood 1987: 69: 924-928.
93. FINAZZI G, BELLAVITA P, FALANGA A, VIERO P, BARBUI T. Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Am J Hematol 1992: 41: 165-169.
94. GUTTERMAN LA. Treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: The role of vincristine. In: KAPLAN BS, TROMPETER RS, MOAKE JL, eds. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker Inc: 1992: 513-530.
95. BYRNES JJ, KHURANA M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977:297: 1386-1389.
96. OBRADOR GT, ZEIGLER ZR, SHADDUCK RK, ROSENFELD CS, HANRAHAN JB. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993: 42: 217-220.
97. REYNOLDS PM, JACKSON JM, BRIME JAS, VIVIAN AB. Thrombotic thrombocytopenic purpura remission following splenectomy. Am J Med 1976: 61: 439-447.
98. RUTKOW IM. Thrombotic thrombocytopenic purpura (TTP) and splenectomy. A current appraisal. Ann Surg 1978: 188: 701-705.
99. ONUNDARSON PT, ROWE JM, HEAL JM, FRANCIS CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med 1992: 152: 791-796.
100. HAYWARD CPM, SUTTON DMC, CARTER WH, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura hemolytic uremic syndrome. Arch Intern Med 1994: 154: 982-988.
101. GREM JL, MERRITT J, CARBONE PP. Treatment of mitomycin-associated microangiopathic hemolytic anemia with vincristine. Arch Intern Med 1986: 146: 566.
102. BIRD JM, CUMMINS D, MACHIN SJ. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura (letter). Lancet 1990: 565-566.
103. MOAKE JL, RUDY CK, TROLL JH, et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985: 20: 73-79.
104. WEINER CP. Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 1987: 24: 119-129.
105. ROZDZINSKI E, HERTENSTEIN B, SCHMEISER T, SEIFRIED E, KURRLE E, HEIMPEL H. Thrombotic thrombocytopenic purpura in early pregnancy with maternal and fetal survival. Ann Hematol 1992: 64: 245-248.
106. SIBAI BM, KUSTERMANN L, VELASCO J. Current understanding of severe preeclampsia, pregnancy-associated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, hemolysis, elevated liver enzymes, and low platelet syndrome, and postpartum acute renal failure: different clinical syndromes or just different names? Curr Opin Nephrol Hypertens 1994: 3: 436-445.
107. SIBAI BM, RAMADAN MK, USTA I, SALAMA M, MERCER BM, FRIEDMAN SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP Syndrome). Am J Obstet Gynecol 1993: 169: 1000-1006.
108. WEINSTEIN L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982: 142: 159-167.
109. REMUZZI G, RUGGENENTI P. Prevention and treatment of pregnancy-associated hypertension: what have we learned in the last 10 years? Am J Kidney Dis 1991: 18: 285-305.
110. THE ECLAMPSIA TRIAL COLLABORATIVE GROUP. Which anti-convulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet 1995: 345: 1455-1463.
111. LUCAS MJ, LEVENO KJ, CUNNINGHAM FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995: 333: 201-205.
112. MAGANN EF, PERRY KG JR, MEYDRECH EF, HARRIS RL, CHAUHAN SP, MARTIN JN JR. Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994: 171 (4): 1154-1158.
113. MAGANN EF, BASS D, CHAUHAN SP, SULIVAN DL, MARTIN RW, MARTIN JN JR. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994: 171 (4): 1148-1153.
114. MARTIN JN, FILES JC, BLAKE PG, PERRY KG JR, MORRISON JC, NORMAL PH. Postpartum plasma exchange for atypical pre-eclampsia eclampsia as HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome. Am J Obstet Gynecol 1995: 172: 1107-1127.
115. MARTIN JN, PERRY KG JR, ROBERTS WE, et al. Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome. J Clin Apheresis 1995: 9 (3): 155-161.
116. ROBSON JS, MARTIN AM, RUCKLEY VA. Irreversible post partum renal failure. A new syndrome. Q J Med 1968: 137: 423-435.
117. AMOROSI EL, KARPATKIN S. Antiplatelet treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1977: 86: 102-106.
118. BOCCIA RV, GELMANN EP, BAKER CC, MARTI G, LONGO DL. A hemolytic uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern Med 1984: 101: 716-717.
119. LEAF AN, LAUBENSTEIN LJ, RAPHAEL B, HOCHSTER H, BAEZ L, KARPATKIN S. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HlV-1) infection. Ann Intern Med 1988: 109: 194-197.
120. FARINA C, GAVAZZENI G, CAPRIOLI A, REMUZZI G. Hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection in acquired immunodeficiency syndrome. Blood 1990: 75: 2465.
121. TUMLIN JA, SANDS JM, SOMEREN A. A hemolytic uremic syndrome following 'crack' cocaine inhalation. Am J Med Sci 1990: 299: 366-371.
122. ARGENBRIGHT LW, BARTON RW. Interactions of leukocyte integrins with intercellular adhesion molecule 1 in the production of inflammatory vascular injury in vivo. J Clin Invest 1992: 89: 259-272.
123. DEKKER A, O'BRIEN ME, CAMMARATA RJ. The association of thrombotic thrombocytopenic purpura with systemic lupus erythematosus. Am J Med Sci 1974: 267: 243-249.
124. LASZLO MH, ALVAREZ A, FELDMAN F. The association of thrombotic thrombocytopenic purpura and disseminated lupus erythematosus: report of a case. Ann Intern Med 1955: 42: 1308-1320.
125. LEVINE S, SHEARN MA. Thrombotic thromboeytopenic purpura and systemic lupus erythematosus. Arch Intern Med 1964: 113: 826-836.
126. ROTHFIELD NF. Systemic lupus erythematosus. In: MCCAREY DJ, ed. Arthritis and Allied Conditions. Philadelphia: Lea and Febiger: 1979: 706.
127. STEINBERG AD, GREEN WT, TALAL N. Thrombotic thrombocytopenic purpura complicating Sjögren's syndrome. JAMA 1971: 215: 757-761.
128. MOREY DA, WITHE JB, DAILY WM. Thrombotic thrombocytopenic purpura diagnosed by random lymph node biopsy. Arch Intern Med 1956: 98: 821-823.
129. BENITEZ L, MATHEWS M, MALLORY GK. Platelet thrombosis with polyarteritis nodosa: report of a case. Arch Pathol 1964: 77: 116-125.
130. LOHRMANN H-P, ADAM W, HEYMER B, KUBANEK B. Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases. Ann Intern Med 1973: 79: 368-375.
131. MURGO AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: KAPLAN BS, TROMPETER RS, MOAKE JL, eds. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker Inc: 1992: 271-297.
132. BLANCO R, GRIFFIN J, RADICE P. Mitomycin-C pulmonary toxicity protective measures. Proc Am Soc Clin Oncol 1986: 5: 48.
133. KOREC S, SCHEIN PS, SMITH FP. Treatment of cancer-associated hemolytic-uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol 1986: 4: 210-215.
134. LESESNE JB, ROTHSCHILD N, ERICKSON B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989: 7: 781-789.
135. CERILLI GJ, NELSON C, DORFMANN L. Renal homotransplantation in infants and children with the hemolytic uremic syndrome. Surgery 1972: 71: 66-71.
136. FOLMAN R, ARBUS GS, CHURCHILL B, GAUM L, HUBER J. Recurrence of the hemolytic uremic syndrome in a 3-1/2 years-old child, 4 months after second renal transplantation. Clin Nephrol 1978: 10: 121-127.
137. Hebert D, Sibley RK, Mauer SM. Recurrence of hemolytic uremic syndrome in renal transplant recipients. Kidney Int 1986: 30: S51-S58.
138. MILLER R, BURKE B, MATAS A, KASHTAN C. Recurrence (R) of hemolytic uremic syndrome (HUS) in renal allografts: a single center report. JASN 1994: 5: 1024 (abstract).
139. GAGNADOUS MF, BROYER M, HABIB R. Renal Transplantation in Hemolytic-Uremic Syndrome. Report of 31 cases. Proceedings of the VIII Congress of the International Pediatric Nephrology Association. Toronto, 27 August-1 September 1989 (abstract).
140. SUTTON DMC, NAIR RC, ROCK G, Canadian Apheresis Study Group. Complications of plasma exchange. Transfusion 1989: 29: 124-126.
141. WU KK. Role of prostacyclin in the pathogenesis and therapy of thrombotic thrombocytopenic purpura. In: KAPLAN BS, TROMPETER RS, MOAKE JL, eds. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, Inc: 1992: 483-489.
142. PHILLIPS MD, MOAKE JL, NOLASCO LH, et al. Aurin tricarboxylic acid: a novel inhibitor of platelet-von Willebrand factor association. Blood 1988: 72: 1898-1903.
143. SUGIMOTO M, RICCA G, HRINDA ME, et al. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry 1991: 30: 5202-5209.
144. 1746. J Biol Chem 1988: 263: 7500-7505.